ONCOGENIC POTENTIAL OF TAMOXIFEN ON ENDOMETRIA OF POSTMENOPAUSAL WOMEN WITH BREAST-CANCER - PRELIMINARY-REPORT

被引:102
作者
GAL, D
KOPEL, S
BASHEVKIN, M
LEBOWICZ, J
LEV, R
TANCER, ML
机构
[1] MAIMONIDES HOSP, DEPT GYNECOL ONCOL, BROOKLYN, NY 11219 USA
[2] MAIMONIDES HOSP, DEPT MED ONCOL, BROOKLYN, NY 11219 USA
[3] SUNY DOWNSTATE MED CTR, BROOKLYN, NY 11219 USA
[4] MAIMONIDES HOSP, DEPT OBSTET & GYNECOL, BROOKLYN, NY 11219 USA
关键词
D O I
10.1016/0090-8258(91)90330-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tamoxifen (TAM), a nonsteroidal antiestrogen, is used for pre- and postmenopausal patients with breast cancer. Recent reports suggest that TAM may cause endometrial neoplasia. This study is designed to evaluate the oncogenic potential of low-dose TAM on the endometrium. Initially, endometrial screening of patients with breast cancer who had received TAM therapy for at least 12 months was conducted. Seventy patients were interviewed and office endometrial biopsies were obtained from thirty-eight patients. Seven (18%) had hyperplastic changes, ranging from simple hyperplasia through complex hyperplasia with atypia. The following prospective study was conducted: after breast surgery and prior to initiation of TAM therapy, an office endometrial sampling was obtained as a control. After initiation of TAM therapy, biopsies were repeated every 4 to 6 months as long as the patients remained asymptomatic. Nineteen patients were interviewed. Twelve patients were biopsied and followed from 3 to 15 months. One patient refused additional biopsies. Eleven patients had repeat biopsies after initiation of TAM. New hyperplastic changes were found in 3 11 (27%) patients. The preliminary results of this study (although with a small number of patients) indicate that TAM may have some neoplastic effect on the endometrium of postmenopausal patients with breast cancer. This study is still in progress. Additional prospective studies are warranted before a significant correlation between TAM and endometrial neoplasia is confirmed. © 1991.
引用
收藏
页码:120 / 123
页数:4
相关论文
共 30 条
[1]  
AMROCH D, 1984, HORMONES CANCER, P633
[2]   4 CASE-REPORTS PRESENTING NEW ACQUISITIONS ON THE ASSOCIATION BETWEEN BREAST AND ENDOMETRIAL CARCINOMA [J].
ATLANTE, G ;
POZZI, M ;
VINCENZONI, C ;
VOCATURO, G .
GYNECOLOGIC ONCOLOGY, 1990, 37 (03) :378-380
[3]  
Burke P, 1987, Minerva Ginecol, V39, P453
[4]   ESTROGEN RECEPTOR - ANTIESTROGEN COMPLEX - ATYPICAL BINDING BY UTERINE NUCLEI AND EFFECTS ON UTERINE GROWTH [J].
CLARK, JH ;
ANDERSON, JN ;
PECK, EJ .
STEROIDS, 1973, 22 (05) :707-718
[5]  
FORNANDER T, 1989, LANCET, V1, P117
[6]   THE PHARMACOLOGY AND CLINICAL USES OF TAMOXIFEN [J].
FURR, BJA ;
JORDAN, VC .
PHARMACOLOGY & THERAPEUTICS, 1984, 25 (02) :127-205
[7]  
GOTTARDIS MM, 1988, CANCER RES, V48, P812
[8]   INVITRO GROWTH-REGULATION OF ENDOMETRIAL CARCINOMA-CELLS BY TAMOXIFEN AND MEDROXYPROGESTERONE ACETATE [J].
GRENMAN, SE ;
ROBERTS, JA ;
ENGLAND, BG ;
GRONROOS, M ;
CAREY, TE .
GYNECOLOGIC ONCOLOGY, 1988, 30 (02) :239-250
[9]  
GUSBERG SB, 1990, CANCER, V65, P1463, DOI 10.1002/1097-0142(19900401)65:7<1463::AID-CNCR2820650702>3.0.CO
[10]  
2-S